EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Approval of First CAR-Ts: Have we Solved all Hurdles for ATMPs?

Diane Seimetz, Karl Heller, Jan Richter

Cell Medicine · 2019

DOI: 10.1177/2155179018822781 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cell Medicine, 2019. Verfasst von Diane Seimetz und 2 weiteren Autor:innen. Beteiligte Einrichtung: Biopharma Excellence GmbH, Munich, Germany. Die Arbeit wurde bisher 84-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

T cells are known as the most potent killer cells of the immune system, designed by nature to prevent unwanted challenges. The first class of therapeutic products harnessing the power of T cells for target-specific treatment of oncological diseases was bispecific antibodies. The first T-cell engaging bispecific antibodies that obtained approval were catumaxomab and blinatumomab 1 , 2 . Eight years later, the first chimeric antigen receptor (CAR)-T cells received regulatory approval 3 . CAR-T cells are the cellular interpretation of T-cell engaging therapies and have shown remarkable clinical results. CAR-T cells belong to the regulatory group of advanced therapy medicinal products (ATMPs). Due to the cell-/gene-based complex nature, ATMPs are far more challenging to develop than other, more defined, medicinal products. Despite very encouraging clinical results, there have been many set-backs in the development of ATMPs during the past 20 years. Therefore, the approval of the first two CAR-Ts KYMRIAH and YESCARTA is highly encouraging for the field. In this article we review the current landscape of CAR-Ts as a special class of ATMPs. This comprises the pathway to approval including the use of dedicated regulatory tools and challenges that were faced during the procedure. Furthermore, we highlight important future trends in the field.

Schlagwörter

Stichwörter der Autor:innen

ATMPCAR-TPRIMERMATgenome editingregulatory strategy

Autor:innen und Institutionen

  • Biopharma Excellence GmbH, Munich, Germany.
  • Shire, Zug, Switzerland.

Zitieren

APA

Seimetz, D., Heller, K., & Richter, J. (2019). Approval of First CAR-Ts: Have we Solved all Hurdles for ATMPs?. Cell Medicine. https://doi.org/10.1177/2155179018822781

Vancouver

Seimetz D, Heller K, Richter J. Approval of First CAR-Ts: Have we Solved all Hurdles for ATMPs?. Cell Medicine. 2019. doi:10.1177/2155179018822781

BibTeX
@article{Seimetz2019,
  author = {Seimetz, Diane and Heller, Karl and Richter, Jan},
  title = {Approval of First CAR-Ts: Have we Solved all Hurdles for ATMPs?},
  journal = {Cell Medicine},
  year = {2019},
  doi = {10.1177/2155179018822781}
}
Kostenlos starten →